Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system

Among the several strategies explored for (1) the enhancement of the immune response to influenza immunization, (2) the improvement of the vaccine acceptability and (3) the overcoming of the egg-dependency for vaccine production, intradermal administration of influenza vaccine emerges as a promising alternative to conventional intramuscular route, thanks to the recent availability of new delivery devices and the perception of advantages in terms of immunogenicity, safety, reduction of antigen content and acceptability. Data from clinical trials performed in children, adults <60 y and elderly people and post-marketing surveillance demonstrate that actually, licensed intradermal influenza vaccines, Intanza™ 9 and 15 µg and Fluzone™ Intradermal, administered by the microinjection system Soluvia™, show an excellent acceptability, tolerability and safety profile. Formulations containing 9 and 15 μg per strain demonstrate, respectively, comparable and superior immunogenicity than conventional intramuscular vaccines. Licensed intradermal influenza vaccines can be considered a valid alternative to standard intramuscular vaccination offering significant advantages in low-responder populations and helping to increase influenza vaccination coverage rates especially in people with fear of needles or high apprehension associated with annual vaccination.

[1]  W. Roper,et al.  Prevention and control of influenza: Part I, Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1994, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[2]  F. Newman,et al.  Serum antibody responses after intradermal vaccination against influenza. , 2004, The New England journal of medicine.

[3]  J. Phair,et al.  Ageing and infection. , 1988, Ciba Foundation symposium.

[4]  B. Guy,et al.  Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice , 2008, Expert review of vaccines.

[5]  C. Caux,et al.  Human Langerhans Cells Express a Specific TLR Profile and Differentially Respond to Viruses and Gram-Positive Bacteria1 , 2006, The Journal of Immunology.

[6]  N. Mickuvienė,et al.  Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial , 2009, BMC medicine.

[7]  R. Rappuoli,et al.  An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. , 2006, Vaccine.

[8]  J. Gerberding,et al.  State-specific influenza vaccination coverage among adults aged > or =18 years--United States, 2003-04 and 2005-06 influenza seasons. , 2007, MMWR. Morbidity and mortality weekly report.

[9]  J. Hickling,et al.  Intradermal delivery of vaccines: potential benefits and current challenges. , 2011, Bulletin of the World Health Organization.

[10]  F. Cutts,et al.  Alternative routes of measles immunization: a review. , 1997, Biologicals : journal of the International Association of Biological Standardization.

[11]  R. Couch,et al.  The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. , 1977, The Journal of infectious diseases.

[12]  F. Ruben,et al.  Intradermal administration of bivalent and monovalent influenza vaccines. , 1977, Annals of allergy.

[13]  P. van Damme,et al.  Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. , 2009, Vaccine.

[14]  S. Esposito,et al.  Immunogenicity and safety of intradermal influenza vaccine in children. , 2011, Vaccine.

[15]  L. Sticchi,et al.  Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. , 2010, Vaccine.

[16]  P. van Damme,et al.  Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study , 2010, BMC infectious diseases.

[17]  P. Perine,et al.  Low-dose intradermal and intramuscular vaccination against hepatitis B. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  W. P. Boger,et al.  [Subcutaneous and intradermal vaccination with Asian influenza vaccine]. , 1957, Journal of the American Medical Association.

[19]  S. Foster,et al.  Comparison of intradermal and subcutaneous routes of cholera vaccine administration. , 1972, Lancet.

[20]  T. Cherian,et al.  Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. , 1998, Vaccine.

[21]  J. Villadangos,et al.  Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. , 2006, Immunity.

[22]  F. de Looze,et al.  Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. , 2008, The Journal of infectious diseases.

[23]  G. Dick,et al.  Antibody response following intradermal or oral administration of formalinised poliomyelitis. , 1958, Lancet.

[24]  M. Prausnitz,et al.  Improved influenza vaccination in the skin using vaccine coated microneedles. , 2009, Vaccine.

[25]  Mark R Prausnitz,et al.  Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[26]  M. Prausnitz,et al.  Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. , 2010, The Journal of infectious diseases.

[27]  A. Monto,et al.  Influenza Control in the 21st Century: Optimizing Protection of Older Adults , 2022 .

[28]  T. H. Weller,et al.  Immunologic Reactions Following the Intradermal Inoculation of Influenza A and B Vaccine.∗ , 1948, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[29]  G. Schuler,et al.  Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. , 1993, The Journal of clinical investigation.

[30]  J. Stockman,et al.  Dissolving polymer microneedle patches for influenza vaccination , 2012 .

[31]  K. Nicholson,et al.  HUMAN DIPLOID CELL STRAIN RABIES VACCINE , 1976, The Lancet.

[32]  A Flahault,et al.  Influenza vaccine: the challenge of antigenic drift. , 2007, Vaccine.

[33]  Kwok-Hung Chan,et al.  Immunogenicity and Safety of Intradermal Influenza Immunization at a Reduced Dose in Healthy Children , 2007, Pediatrics.

[34]  F. Marincola,et al.  Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin’s Lymphoma Patients Treated with Rituximab-Containing Regimens , 2011, The Journal of Immunology.

[35]  E. Morelon,et al.  Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. , 2010, Vaccine.

[36]  E. Lewis,et al.  Intradermal inoculation with Heptavax-B. Immune response and histologic evaluation of injection sites. , 1989, JAMA.

[37]  Ruben Fl,et al.  Intradermal administration of bivalent and monovalent influenza vaccines. , 1977 .

[38]  M. Klein,et al.  The response of infants and children to Asian influenza vaccine administered by intradermal and subcutaneous routes. , 1961, The Journal of pediatrics.

[39]  C. A. Phillips,et al.  Purified influenza vaccine: clinical and serologic responses to varying doses and different routes of immunization. , 1970, The Journal of infectious diseases.

[40]  T. Cate,et al.  Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. , 2011, Vaccine.

[41]  P. van Damme,et al.  Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. , 2009, Vaccine.

[42]  M. Schwenkglenks,et al.  Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons , 2008, BMC public health.

[43]  D. Francis,et al.  INTRADERMAL HEPATITIS B VIRUS VACCINE: IMMUNOGENICITY AND SIDE-EFFECTS IN ADULTS , 1983, The Lancet.

[44]  J. Sirard,et al.  Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. , 2006, Immunity.

[45]  V. Nguyen,et al.  Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials , 2010, Human vaccines.

[46]  Kyoung-Mi Park,et al.  Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. , 2010, Antiviral research.

[47]  Victoria F. Keeton,et al.  Immunization updates and challenges , 2010, Current opinion in pediatrics.

[48]  A. Nicoll,et al.  Risk groups and other target groups - preliminary ECDC guidance for developing influenza vaccination recommendations for the season 2010-11. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[49]  J. Kaldor,et al.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[50]  Cécile Viboud,et al.  Antibody response to influenza vaccination in the elderly: a quantitative review. , 2006, Vaccine.

[51]  P. Lambert,et al.  Intradermal vaccine delivery: will new delivery systems transform vaccine administration? , 2008, Vaccine.

[52]  M. Frank,et al.  Willingness to vaccinate or get vaccinated with an intradermal seasonal influenza vaccine: a survey of general practitioners and the general public in France and Germany , 2011, Advances in therapy.

[53]  Szwed Jj,et al.  Response to intradermal vaccination with A2, Hong Kong variant, influenza vaccine. , 1969 .

[54]  D. Warrell,et al.  ECONOMICAL MULTIPLE-SITE INTRADERMAL IMMUNISATION WITH HUMAN DIPLOID-CELL-STRAIN VACCINE IS EFFECTIVE FOR POST-EXPOSURE RABIES PROPHYLAXIS , 1985, The Lancet.

[55]  Marks Mi,et al.  Intradermal influenza immunization. Experience with Hong Kong vaccine. , 1971 .

[56]  A. Osterhaus,et al.  Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine‐induced antibody response to this strain in the elderly , 2000, Journal of medical virology.

[57]  R. Larke,et al.  Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. , 1979, The Journal of infectious diseases.

[58]  H. Margolis,et al.  Intradermal hepatitis B vaccination in an abbreviated schedule. , 1986, Vaccine.

[59]  G. Leroux-Roels,et al.  Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. , 2008, Vaccine.

[60]  F. Hayden,et al.  Influenza vaccination of health care workers in hospitals--a review of studies on attitudes and predictors. , 2009, Vaccine.

[61]  S. Plotkin,et al.  Vaccines: the Fourth Century , 2009, Clinical and Vaccine Immunology.

[62]  Kwok-Hung Chan,et al.  Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. , 2009, Vaccine.

[63]  J. Szwed,et al.  Response to intradermal vaccination with A2, Hong Kong variant, influenza vaccine. , 1969, The New England journal of medicine.

[64]  P. Laurent,et al.  Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. , 2007, Vaccine.

[65]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[66]  W. Bancroft,et al.  Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. , 1985, JAMA.

[67]  T. Szucs,et al.  Influenza Vaccination Coverage Rates in 5 European Countries: a Population-Based Cross-Sectional Analysis of the Seasons 02/03, 03/04 and 04/05 , 2007, Infection.

[68]  L. Sticchi,et al.  Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. , 2008, Vaccine.

[69]  M. Goldfield,et al.  A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. , 1979, American journal of public health.

[70]  T. Cherian,et al.  Immune response of infants to inactivated poliovirus vaccine injected intradermally. , 1992, Vaccine.

[71]  M. Marks,et al.  Intradermal influenza immunization. Experience with Hong Kong vaccine. , 1971, The American review of respiratory disease.

[72]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[73]  K. Johansen,et al.  Protection against poliomyelitis in Europe. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[74]  C. Thompson,et al.  Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. , 1993, Journal of immunology.

[75]  J. Mccarroll,et al.  Immunization with Asian-strain influenza vaccine: equivalence of the subcutaneous and intradermal routes. , 1958, New England Journal of Medicine.

[76]  M. Cooney,et al.  Efficacy of intradermally administered A2 Hong Kong vaccine. , 1970, JAMA.

[77]  J. Goss,et al.  Vaccinations for Adult Solid-Organ Transplant Recipients: Current Recommendations and Protocols , 2003, Clinical Microbiology Reviews.

[78]  A. Ambrozaitis,et al.  Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, Phase III trial , 2010, Human vaccines.

[79]  Y. Maeno,et al.  Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. , 2008, Vaccine.

[80]  Wilbur H. Chen,et al.  Bench-to-bedside review: Vaccine protection strategies during pandemic flu outbreaks , 2010, Critical care.

[81]  B. Spellberg.  The cutaneous citadel: a holistic view of skin and immunity. , 2000, Life sciences.

[82]  A. Banzhoff,et al.  Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. , 2000, Bulletin of the World Health Organization.

[83]  T. Kase,et al.  Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine. , 2006, Vaccine.

[84]  M. Prausnitz,et al.  Microneedle Vaccination with Stabilized Recombinant Influenza Virus Hemagglutinin Induces Improved Protective Immunity , 2011, Clinical and Vaccine Immunology.

[85]  A. Laurent,et al.  Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. , 2007, Vaccine.

[86]  T. Cherian,et al.  Immune response to intradermally injected inactivated poliovirus vaccine , 1991, The Lancet.

[87]  J. Wood,et al.  The influenza vaccine licensing process. , 2003, Vaccine.